Weekly Digest
Short, dated summaries of the latest studies and developments that matter for APOE4 carriers, each linked back to the original source.
The arrival of anti-amyloid antibodies makes your APOE status relevant to treatment safety, not just to risk. The short version.
Source: Alzheimer’s Association: Lecanemab (Leqembi)
Often symptomless, and one of the best-established modifiable dementia risk factors. Don’t let it slip under the radar.
Source: World Health Organization: Dementia
What this digest is, who it’s for, and how to get the most out of it.
Why the modifiable-risk-factor framing matters so much for APOE4 carriers, and what the WHO actually says about reducing risk.
Source: World Health Organization: Dementia